E Raymond

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi [Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]
    Marie Paule Sablin
    Service inter hospitalier de cancérologie Bichat Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy
    Bull Cancer 94:S149-54. 2007
  2. ncbi Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
    Eric Raymond
    Service inter hospitalier de cancérologie, Beaujon University Hospital, Clichy
    J Clin Oncol 26:4659-65. 2008
  3. ncbi Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells
    Maria Serova
    EMI0334, , Paris, France
    Cancer Chemother Pharmacol 57:491-9. 2006
  4. ncbi Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Sandrine Faivre
    Department of Medicine, Gustave-Roussy Institute, Villejuif, France
    J Clin Oncol 24:25-35. 2006
  5. ncbi A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
    Werner Hilgers
    , Paris, France
    Invest New Drugs 24:311-9. 2006
  6. ncbi Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells
    Eric Raymond
    INSERM U482, Hopital Saint Antoine, Paris, France
    Int J Oncol 21:361-7. 2002
  7. ncbi Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
    E Raymond
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94815 Villejuif, France
    Eur J Cancer 38:1348-50. 2002
  8. ncbi Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas
    E Raymond
    Institute for Drug Development Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 7:1171-80. 2001
  9. ncbi Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction
    Eric Raymond
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    J Clin Oncol 20:4303-12. 2002
  10. ncbi Cellular and molecular pharmacology of oxaliplatin
    Eric Raymond
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Mol Cancer Ther 1:227-35. 2002

Detail Information

Publications73

  1. ncbi [Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]
    Marie Paule Sablin
    Service inter hospitalier de cancérologie Bichat Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy
    Bull Cancer 94:S149-54. 2007
    ..Taken together, these recent data should result in a better and more specific use of these two very promising drugs...
  2. ncbi Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
    Eric Raymond
    Service inter hospitalier de cancérologie, Beaujon University Hospital, Clichy
    J Clin Oncol 26:4659-65. 2008
    ..To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas...
  3. ncbi Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells
    Maria Serova
    EMI0334, , Paris, France
    Cancer Chemother Pharmacol 57:491-9. 2006
    ..Based on these data, irofulven-oxaliplatin and cisplatin-irofulven combinations will be further explored in clinical trials, favoring the use schedules of oxaliplatin given prior to irofulven in patients with cancer...
  4. ncbi Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Sandrine Faivre
    Department of Medicine, Gustave-Roussy Institute, Villejuif, France
    J Clin Oncol 24:25-35. 2006
    ..Future studies may consider including prospective imaging techniques such as high frequency ultrasound to monitor tumor density...
  5. ncbi A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
    Werner Hilgers
    , Paris, France
    Invest New Drugs 24:311-9. 2006
    ..CONCLUSION: Irofulven with cisplatin was adequately tolerated and substantial evidence of antitumor activity was observed. The recommended dose is irofulven 0.4 mg/kg and cisplatin 30 mg/m2...
  6. ncbi Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells
    Eric Raymond
    INSERM U482, Hopital Saint Antoine, Paris, France
    Int J Oncol 21:361-7. 2002
    ..These results argue in favor of clinical trials of chemotherapy combining MTA with oxaliplatin or irinotecan (CPT-11), for the treatment of patients with colon cancer...
  7. ncbi Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
    E Raymond
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94815 Villejuif, France
    Eur J Cancer 38:1348-50. 2002
    ..The response rate was poor, with 5 patients experiencing tumour stabilisation and 10 progressing. Thus, the results do not support the further evaluation of RFS2000 as a single agent in patients with recurrent GBM...
  8. ncbi Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas
    E Raymond
    Institute for Drug Development Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 7:1171-80. 2001
    ..This clinical trial investigated whether a noncytotoxic dose of oral hydroxyurea could reduce the number of dmins in cancer cells in patients with advanced ovarian carcinomas...
  9. ncbi Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction
    Eric Raymond
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    J Clin Oncol 20:4303-12. 2002
    ..To determine the recommended dose (RD) and the pharmacokinetic profile of irinotecan and its metabolites in cancer patients with hyperbilirubinemia...
  10. ncbi Cellular and molecular pharmacology of oxaliplatin
    Eric Raymond
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Mol Cancer Ther 1:227-35. 2002
    ..In vitro and preclinical combination data that could optimize oxaliplatin-based chemotherapy are also reviewed...
  11. ncbi Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
    E Raymond
    Department of Medicine, Institute Gustave Roussy, Villejuif, France
    Drugs 60:15-23; discussion 41-2. 2000
    ..As our knowledge of signal transduction pathways in cancer increases, it is hoped that further advances in this area will allow the therapeutic potential of these compounds as anticancer agents to be realised...
  12. ncbi Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma
    E Raymond
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 14:603-14. 2003
    ..To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma multiforme...
  13. ncbi DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs
    E Raymond
    Department of Medicine, Institute Gustave Roussy, Villejuif, France
    Invest New Drugs 18:123-37. 2000
    ..In this paper, we review the most recent information concerning the regulation of telomere length and telomerase expression, with emphasis on mechanisms that might translate into new drug discovery...
  14. ncbi Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer
    E Raymond
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 20:3508-21. 2002
    ..The objectives were to determine the maximum-tolerated dose, the recommended dose, the dose-limiting toxicity, the pharmacokinetics, and the activity of E7070, a novel cell-cycle inhibitor...
  15. ncbi Activity of temozolomide against human tumor colony-forming units
    E Raymond
    Translational Research Laboratory, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 3:1769-74. 1997
    ..These data indicate both that temozolomide is an active drug in vitro against a large variety of human tumors, including some tumors usually resistant to conventional chemotherapy, and that further clinical evaluation is warranted...
  16. ncbi Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells
    E Izbicka
    Institute for Drug Development, San Antonio, Texas 78245, USA
    Cancer Res 59:639-44. 1999
    ..Moreover, the data support the concept that a rational, structure-based approach is possible to design novel telomere-interactive agents with application to a selective and specific anticancer therapy...
  17. ncbi Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos
    E Izbicka
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Anticancer Drug Des 14:355-65. 1999
    ..Our data suggest that G4-interactive agents exert their antiproliferative effects via chromosomal destabilization and warrant their further development as valuable anticancer tools...
  18. ncbi Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma
    S Faivre
    Department of Medicine, Institut Gustave-Roussy, Villejuif, France
    Ann Oncol 13:1479-89. 2002
    ..The RD was gemcitabine 1500 mg/m(2) and oxaliplatin 85 mg/m(2) every 2 weeks. Promising antitumor activity was reported in patients with NSCLC and platinum-pretreated OC, and thus, deserves further evaluation...
  19. ncbi Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer
    C Monnerat
    Department of Medicine, Institut Gustave-Roussy, Villejuif, France
    Ann Oncol 15:316-23. 2004
    ..CONCLUSIONS: The results of the present study indicate that PKC412 at a dose of 50 mg/day can be safely added to cisplatin and gemcitabine in patients with advanced non-small-cell lung cancer...
  20. ncbi Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
    S Faivre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer Chemother Pharmacol 44:117-23. 1999
    ..This study assessed the cytotoxic effects of the nucleoside analog gemcitabine in combination with the diaminocyclohexane platinum compound oxaliplatin...
  21. ncbi A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies
    S Faivre
    Department of Medicine, Institut Gustave-Roussy, Villejuif, France
    Clin Cancer Res 7:43-50. 2001
    ..This lead compound of the aza-anthracenedione family shows promising antitumor activity and deserves Phase II investigation in patients with high risk of cumulative cardiotoxicity, such as anthracycline-pretreated breast cancer patients...
  22. ncbi Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice
    C Louvet
    INSERM Unit 482, Hopital St Antoine, Paris, France
    Anticancer Drugs 11:579-82. 2000
    ..05) or UFT/FA (p<0.05). These results demonstrate the synergistic effect of the combination of oxaliplatin, UFT and FA in this HT29 cell xenograft model, and warrant further investigations in patients with metastatic colorectal cancer...
  23. ncbi Activity of oxaliplatin against human tumor colony-forming units
    E Raymond
    Nordan Colon Cancer Research and Translational Research Laboratory, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245, USA
    Clin Cancer Res 4:1021-9. 1998
    ....
  24. ncbi Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
    G Bousquet
    Department of Oncology, APHP Saint Louis Hospital, Paris, France
    Br J Cancer 105:1640-5. 2011
    ..Currently, the molecule is in phase III development for second-line non-small cell lung cancer and first-line ovarian cancer patients...
  25. ncbi Oxaliplatin-induced damage of cellular DNA
    J M Woynarowski
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, USA
    Mol Pharmacol 58:920-7. 2000
    ..However, oxaliplatin requires fewer DNA lesions than does cisplatin to achieve cell growth inhibition...
  26. ncbi In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
    E Izbicka
    Institute for Drug Development-Cancer Therapy and Research Center, San Antonio, TX, USA
    Ann Oncol 9:981-7. 1998
    ....
  27. ncbi Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro
    H Soda
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Prostate 43:161-8. 2000
    ..Recent studies have shown that sex hormones regulate telomerase activity in endometrium and breast tissues. The present study was designed to clarify the effects of androgen on telomerase activity in normal and malignant prostate cells...
  28. ncbi Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors
    K Vera
    Department of Medicine, Institute Gustave-Roussy, Villejuif, France
    Ann Oncol 15:161-71. 2004
    ..Objective responses were reported in 13 patients. CONCLUSIONS: Temozolomide can be given safely using a dose-dense regimen of 300 mg/m(2)/day for 3 consecutive days every 2 weeks in patients with recurrent brain tumors...
  29. ncbi [Epidermoid carcinoma of the head and neck: contribution of chemotherapy in case of recurrence and locally advanced disease. Review of the literature]
    A Hasbini
    Institut Gustave Roussy, Departement de Medecine, Villejuif, France
    Ann Otolaryngol Chir Cervicofac 117:390-402. 2000
    ..In locally advanced disease, concomitant chemotherapy with radiotherapy seems to give a minimal but real benefit as evidenced in the different meta-analyses recently published...
  30. ncbi A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay
    E Raymond
    Human Telomerase Working Group, Institute for Drug Development Cancer Therapy and Research Center, San Antonio, TX 78245 3217, USA
    Br J Cancer 80:1332-41. 1999
    ..Based on these results, a breast cancer model for evaluating telomerase and telomere interactive agents is proposed...
  31. ncbi [Epidermal growth factor inhibitors]
    C Delbaldo
    , Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Cedex, Villejuif, France
    Rev Med Interne 24:372-83. 2003
    ....
  32. ncbi Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial
    J P Durand
    Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Paris, France
    Ann Oncol 23:200-5. 2012
    ..Oxaliplatin neurosensory toxicity is dose limiting and may present as acute symptoms and/or cumulative peripheral neuropathy...
  33. ncbi End points for new agents in induction chemotherapy for locally advanced head and neck cancers
    C Monnerat
    Departments of Medicine, Head and Neck Surgery and Radiotherapy, Institut Gustave-Roussy, Villejuif, France
    Ann Oncol 13:995-1006. 2002
    ..Finally, we have examined the impact of new cytotoxic agents and present the promising results of new taxane-based combinations...
  34. ncbi Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity
    S Delaloge
    , Villejuif, France
    J Clin Oncol 19:1248-55. 2001
    ..2 months. CONCLUSION: ET-743 has activity in advanced, highly pretreated STS and osteosarcoma patients and warrants further trials to establish the extent of its activity in this setting...
  35. ncbi Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
    D Aguirre
    Department of Clinical Biology, Institute Gustave Roussy, Villejuif, Tumor Immunology Laboratory FRE2443 CNRS, University Rene Descartes Paris 5, France
    Apoptosis 9:797-805. 2004
    ..Furthermore, strategies to down regulate Bcl-2 in ovarian cancer may prove useful in combination with rapamycin or RAD001 for ovarian cancer...
  36. ncbi [Acute alveolo-interstitial pneumopathies in HIV-negative patients treated with antineoplastic chemotherapy]
    C Locher
    , Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France
    Rev Med Interne 23:175-81. 2002
    ..CONCLUSION: The possible role of chemotherapy, corticotherapy and malignant tumor in the pathogenesis of opportunistic infections will be discussed...
  37. ncbi The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival
    M T Rubio
    INSERM U487 Cytokines et Immunologie des Tumeurs Humaines, IFR54, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Int J Oncol 25:407-12. 2004
    ..These findings suggest that DC may be potential targets of cytotoxic drugs and point out the possible impairment of the immunocompetence of these cells following chemotherapy...
  38. ncbi [Irinotecan and liver dysfunctions]
    Marie Paule Sablin
    Service inter hospitalier de cancérologie Bichat Beaujon, Hopital Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Therapie 62:111-5. 2007
    ..In addition, gene polymorphism of UGT1A1 was shown to be associated with a higher risk of toxicity. However, studies are still required to optimise the use of irinotecan in patients with liver dysfunctions...
  39. ncbi [Phase I cancer trials methodology]
    Christophe Le Tourneau
    Service inter hospitalier de cancérologie, Hopital Beaujon, 100, boulevard du General Leclerc, 92110 Clichy
    Bull Cancer 94:943-51. 2007
    ..Alternatives to determine the optimal biological dose include measurement of target inhibition, pharmacokinetic analysis and functional imaging...
  40. ncbi Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies
    Sandrine Faivre
    Department of Medicine, Institute Gustave-Roussy, Villejuif, France
    J Clin Oncol 23:7871-80. 2005
    ..CONCLUSION: Muscle toxicity was dose limiting in this study. Recommended doses of aplidine were 5 and 7 mg/m(2) without and with carnitine, respectively. The role of carnitine will be further explored in phase II studies...
  41. ncbi Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors
    Catherine Delbaldo
    Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Invest New Drugs 26:35-43. 2008
    ..Etaracizumab was well-tolerated at doses up to 6 mg/kg with no evidence of immunogenicity. The safety profile of etaracizumab warrants further exploration in ongoing phase I/II trials...
  42. ncbi Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies
    Herve Ghesquieres
    Department of Medicine, Institut Gustave Roussy, Villejuif
    Invest New Drugs 24:413-21. 2006
    ..5 mg/m2/d topotecan on days 1-5. This study results suggest that alternative schedules of this combination are required...
  43. ncbi Current development of mTOR inhibitors as anticancer agents
    Sandrine Faivre
    Service Inter Hospitalier de Cancrologie, Beaujon University Hospital, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Nat Rev Drug Discov 5:671-88. 2006
    ..Here we review the clinical development of this drug class and look at future prospects for incorporating these agents into multitarget or multimodality strategies against cancer...
  44. ncbi A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors
    Jerome Alexandre
    Hopital Cochin, Universite Paris 5, Paris, France
    Invest New Drugs 25:453-62. 2007
    ..To determine the maximum tolerated dose (MTD), recommended dose, dose limiting toxicities (DLT), safety and pharmacokinetics of irofulven combined with capecitabine in advanced solid tumor patients...
  45. ncbi Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
    Sophie De Bouard
    GRECAN, Centre Francois Baclesse, Universié de Caen Basse Normandie, 14076 Caen, France
    Neuro Oncol 9:412-23. 2007
    ..Sunitinib exhibited potent antiangiogenic activity that was associated with a meaningful prolongation of survival of mice bearing intracerebral GBM. These data support the potential utility of sunitinib in the treatment of GBM...
  46. ncbi Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    Anne-Marie Coudray
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
    Int J Oncol 27:553-61. 2005
    ..These encouraging results warrant further preclinical investigations and clinical trials on the use of BGC9331 combined with SN-38/CPT-11 in treatment of patients with advanced colorectal or gastric cancers...
  47. ncbi Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
    Charlotte Van Kesteren
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands
    Invest New Drugs 23:225-34. 2005
    ..A semi-physiological model was successfully applied to describe the time course and extent of the neutropenia and thrombocytopenia after indisulam administration for four treatment schedules...
  48. ncbi Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status
    Przemyslaw Bozko
    Department of Pharmaceutical Technology and Biochemistry, , Poland
    Acta Biochim Pol 49:109-19. 2002
    ..These results strongly suggest that even prolonged cell cycle arrest in the G2 phase of the cell cycle is not necessarily coupled to efficient DNA repair and enhanced cellular survival as generally believed...
  49. ncbi Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients
    Jerome Alexandre
    service de médecine interne 1, Hopital Cochin, Paris, France
    Clin Cancer Res 10:3377-85. 2004
    ..administered in intermittent weekly schedules in patients with advanced solid tumors...
  50. ncbi Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells
    Virginie Poindessous
    Group of Biology and Pharmacogenetics of Human Tumors, CNRS UMR 8113, , Cachan and Institut Gustave-Roussy, Villejuif, France
    Int J Oncol 23:1347-55. 2003
    ..The enhanced cytotoxicity of irofulven in combination with cisplatin and 5-FU support the clinical application of these regimens...
  51. ncbi Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    ANNE O'DONNELL
    Royal Marsden Hospital, Sutton, Surrey, UK
    J Clin Oncol 26:1588-95. 2008
    ..To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001)...
  52. ncbi Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
    Eric Raymond
    Department of Medicine, Gustave Roussy Institute, Vellefaux, France
    J Clin Oncol 22:2336-47. 2004
    ..To establish the safety, tolerability, and pharmacokinetic parameters of CCI-779, a selective inhibitor of the mammalian target of rapamycin, in patients with advanced cancer...
  53. ncbi Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies
    Sandrine Faivre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Eur J Cancer 44:674-82. 2008
    ..Promising antitumour activity was observed in patients with platinum-pretreated lung cancer...
  54. ncbi Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells
    Florence Koeppel
    Group of Biology and Pharmacogenetics of Human Tumors, Centre National de la Recherche Scientifique, UMR 8113, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 10:5604-13. 2004
    ..To facilitate additional clinical development, we have aimed to identify biological markers associated with sensitivity to the compound...
  55. ncbi Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck
    Sandrine Faivre
    Department of Head and Neck Surgery, Department of Head and Neck Surgery, Gustave-Roussy Institute, 39 rue Camille-Desmoulins, 94805 Villejuif Cedex, France
    Head Neck 27:311-9. 2005
    ..5 years. CONCLUSIONS: Sequential induction chemotherapy is feasible and active in patients with locally advanced head and neck cancers and may further include recent compounds such as taxanes...
  56. ncbi Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data
    Chiaki Tanaka
    Novartis Pharmaceuticals Corp, East Hanover, NJ, USA
    J Clin Oncol 26:1596-602. 2008
    ....
  57. ncbi Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
    Maria Serova
    Institut National de la Sante et de la Recherche Medicale U728 RAYLAB and Department of Medical Oncology, Beaujon University Hospital, Clichy, France
    Mol Cancer Ther 7:915-22. 2008
    ..This study supports ongoing efforts targeting PKC isoforms in cancer therapy with PEP005 alone and in combination with other cytotoxic agents...
  58. ncbi Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
    Nasredine Aissat
    Department of Experimental Pharmacology RayLab and Medical Oncology, Beaujon University Hospital, AP HP, Clichy, France
    Cancer Chemother Pharmacol 62:305-13. 2008
    ..This study aimed to evaluate molecular and cellular effects of rapamycin in a panel of cell lines either as single agent or in combination with cytotoxics commonly used in HNSCC...
  59. ncbi The role of integrins in colorectal cancer
    Christophe Le Tourneau
    Service inter hospitalier de cancérologie, Bichat Beaujon Beaujon University Hospital, Clichy, France
    Oncology (Williston Park) 21:21-4. 2007
    ..Integrin inhibition alone and with other targeted therapeutic approaches should be further investigated in clinical trials in patients with colorectal cancer...
  60. ncbi New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors
    Sandrine Faivre
    Department of Medical Oncology, , Clichy Cedex, Clichy, France
    Semin Oncol 33:407-20. 2006
    ..In this review, we will use the most recent preclinical and clinical data to describe this emerging paradigm for anticancer therapy involving targeting multiple signaling pathways with tyrosine or serine/threonine kinase inhibitors...
  61. ncbi Molecular basis for sunitinib efficacy and future clinical development
    Sandrine Faivre
    Service Inter Hospitalier de Cancérologie SIHC Beaujon Bichat and RayLab, Hopital Beaujon, APHP and Denis Diderot University, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    Nat Rev Drug Discov 6:734-45. 2007
    ....
  62. ncbi Could we expect to improve survival in small cell lung cancer?
    Ghassan El Maalouf
    Department of Medical Oncology, Hopital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France
    Lung Cancer 57:S30-4. 2007
    ..Although further follow-up of patients in this trial is necessary to define response durability and survival, results so far have led to the initiation of phase III trials of pemetrexed-based regimens in ES-SCLC...
  63. ncbi Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Clin Cancer Res 9:2040-8. 2003
    ..They appeared to be a sensitive tool to monitor clinical changes for the five tumor types in these trials and showed that ZD1839 has the potential to improve patients' QoL...
  64. ncbi Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials
    Laurent Meijer
    Station Biologique de Roscoff, C.N.R.S, BP 74, 29682 Roscoff Cedex, Bretagne, France
    Acc Chem Res 36:417-25. 2003
    ....
  65. ncbi Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin
    Virginie Poindessous
    Laboratory of Biology and Pharmacogenetics of Human Tumors, , , Cachan and Institut Gustave-Roussy, Villejuif 94805 cedex, France
    Clin Cancer Res 9:2817-25. 2003
    ..Furthermore, irofulven is not or only marginally affected by resistance mechanisms limiting the efficacy of other alkylating agents...
  66. ncbi Are natural products still of interest compared with molecular-targeted therapy for the treatment of cancer?
    Eric Raymond
    Clin Lung Cancer 5:313. 2004
  67. ncbi Soft tissue sarcomas. Case 3. Gastrointestinal stromal tumor and Carney's triad
    Alain Spatz
    Department of Pathology, Institute Gustave-Roussy, Villejuif, France
    J Clin Oncol 22:2029-31. 2004
  68. ncbi Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck
    Sandrine Faivre
    Department of Medicine, Institut Gustave Roussy, Villejuif Cedex, France
    Eur J Cancer 40:1517-21. 2004
    ..Caelyx has activity against locally recurrent SCCHN and is well tolerated up to 45 mg/m2, but a careful utilisation of this drug is required for tumours relapsing in irradiated areas...
  69. ncbi Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma
    Catherine Delbaldo
    Department of Medicine and Department of Clinical Biochemistry, Institut Gustave-Roussy, Villejuif, France
    Eur J Cancer 41:1739-45. 2005
    ..From this study, we conclude that there is no evidence of pharmacokinetic interaction between irinotecan and cetuximab...
  70. ncbi Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Caroline Robert
    Ann Intern Med 143:313-4. 2005
  71. ncbi Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands
    Sandrine Faivre
    J Clin Oncol 23:6271-3; author reply 6273-4. 2005
  72. ncbi Preclinical and clinical development of novel agents that target the protein kinase C family
    Maria Serova
    U716, Hopital Saint-Louis, Paris, France
    Semin Oncol 33:466-78. 2006
    ....
  73. ncbi Tyrosine kinase inhibition and grey hair
    Caroline Robert
    Lancet 361:1056. 2003